A retrospective chart review of 4,925 human African trypanosomiasis patients treated with melarsoprol in 2001–2003 in Equateur Nord Province of the Democratic Republic of Congo showed a treatment failure rate of 19.5%. This rate increased over the 3 years. Relapse rates were highest in the central part of the province

Boelaert, Marleen

Kande, Victor Betu Ku Mesu

Lutumba, Pascal

Nyamowala, Gaspard

Robays, Jo

Sese, Claude

Van der Veken, Wim

Crossref

Directory of Open Access Journals

PubMed Central

Tropmed Central Antwerp

English

DFMO is a cost effective alternative to melarsoprol for the treatment of second stage human West-African trypanosomiasis in Caxito, Angola. Trop Med Int Health.

Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health.

Prospects for improving African trypanosomiasis chemotherapy.

The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health.

The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health.

Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda. Bull Soc Pathol Exot.

Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials.

Trypanosomiasis control, Democratic Republic of Congo, 1993–2003. Emerg Infect Dis.

High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo